Presidential symposium 3
567O_PR - First International Randomized Study in Malignant Progressive Pheochromocytoma and Paragangliomas (FIRSTMAPPP): An academic double-blind trial investigating sunitinib
Eric Baudin, et al.
After 8 years of enrolment, this first randomized study in the field of MPP provides the highest level of evidence ever reached in this very rare cancer. Sunitinib becomes the first-line option in patients with progressive MPP.
1557O - Adaptive immunity to SARS-CoV-2 infection and vaccination in cancer patients: The CAPTURE study
Scott T. Shepherd, et al.
Patients with HM had blunted humoural responses to infection and vaccination, particularly against VOCs, but preserved cellular responses might contribute to protection. Our results lend support to prioritisation of all cancer patients for further booster vaccination.
LBA8 - Vaccination against SARS-CoV-2 in patients receiving chemotherapy, immunotherapy, or chemo-immunotherapy for solid tumors
Sjoukje Oosting, et al.
mRNA-1273 vaccination is safe in the patient populations studied. For each cohort, the proportion of patients with a SARS- CoV-2-binding antibody response after two vaccinations is non-inferior compared to individuals without cancer. However, a significant minority lacks an adequate response. Most patients have an antibody concentration increase after the second vaccination. Therefore, an additional booster may turn inadequate into adequate responders.
LBA9 - IMpower010: Sites of relapse and subsequent therapy from a phase III study of atezolizumab vs best supportive care after adjuvant chemotherapy in stage IB-IIIA NSCLC
Enriqueta Felip, et al.
At this interim DFS analysis, relapse rate was higher in the BSC vs atezo arm, but there was no clear difference in pattern of relapse between the arms among pts with relapse. Post-relapse CIT use was higher in the BSC arm.